Recently, the PCL raw material independently developed by eSUNMed has been officially listed as new cosmetic ingredients, marking a key compliance breakthrough for the company in the application of biomaterials in cosmetics. This success not only grants the material legal market access, making it one of the few domestically available slow-release carrier alternatives to imported options in this field, but also demonstrates eSUNMed’s comprehensive capabilities in the R&D and industrialization of high-end functional ingredients. It provides a practical technological pathway for the innovative upgrading of domestically produced cosmetic raw materials.
Based on the biocompatibility and controllable biodegradation properties of PCL, its main application directions are clearly defined: first, as a microsphere or nanocapsule carrier to achieve targeted delivery and long-acting controlled release of active ingredients such as vitamins and peptides; second, as a skin tissue engineering material to promote collagen regeneration in anti-wrinkle and repair products, supporting the development of more efficient and intelligent next-generation efficacy-driven skincare products.
As the cosmetics industry moves toward “precision skincare” and “evidence-based efficacy,” the prospects for PCL raw materials are broad. They are expected to drive industry upgrading from the raw material level, fostering a range of high value-added products featuring “sustained and controlled release” and “microneedle transdermal delivery” as advanced technological concepts. As a pioneer, eSUNMed’s successful filing provides a critical domestic technological option for this field and offers new foundational material support for industry innovation.